Sunakshi Sharma, Sanjay Bhat* and Zahoor Ahmed
Neuroleptic malignant syndrome is a rare, life threatening neurologic emergency characterized by fever, rigidity, autonomic instability, mental status changes and an elevated creatine kinase level. It often occurs shortly after the initiation of neuroleptic treatment, or after dose increase. The management of patients with NMS is based upon clinical severity and includes supportive care, withdrawal of antipsychotic agent and agents like bromocriptine and dantrolene. Complications include acute renal failure associated with rhabdomyolysis, respiratory failure, electrolyte imbalance, hepatic failure, seizures from hyperthermia and metabolic derangements, etc.
